View Future GrowthALR Technologies SG 過去の業績過去 基準チェック /06ALR Technologies SGの収益は年間平均-24.4%の割合で減少していますが、 Medical Equipment業界の収益は年間 増加しています。収益は年間15.3% 11.1%割合で 増加しています。主要情報-24.44%収益成長率-17.74%EPS成長率Medical Equipment 業界の成長8.90%収益成長率11.14%株主資本利益率n/aネット・マージンn/a前回の決算情報31 Dec 2025最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Jan 02ALR Technologies SG Ltd. Announces the Successful Completion of Internal Manufacturing Testing on the GluCurve Pet CGMALR Technologies SG Pte. Ltd. announced the successful completion of internal manufacturing testing on the GluCurve Pet CGM showing accuracy results comparative to the leading veterinary Blood Glucose Meter ("BGM") and scheduling of its relaunch into the Canadian market for January 2026. One can't prick the finger of a cat or dog to check blood sugar as you would with a human, and even when you can draw blood from their ear, paw, or vein, a spot check of this nature doesn't provide the data needed to properly dose insulin or see trends as a CGM would. The company believe this is why the company have received so much interest and demand for the GluCurve pet CGM from veterinarians, pet owners, and animal health companies, because there is a desperate need for a holistic product like to manage diabetic dogs. The relaunch of the GluCurve PetCGM in the United States is planned for early second quarter 2026 through an ongoing strategic relationship with a leading veterinary distributor, followed by a global launch throughout Europe, Australia, Asia, South America, and the rest of the world. The company will announce when GluCurve is for sale in Canada and any additional updates on sales, partnerships, and other material updates as they occur.お知らせ • May 02ALR Technologies SG Ltd. announced delayed 20-F filingOn 05/01/2025, ALR Technologies SG Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC.お知らせ • Dec 28ALR Technologies Inc. Provides Sales Guidance for the December, Fourth Quarter of 2022 and First Quarter of 2023ALR Technologies Inc. provided sales guidance for the December, fourth quarter of 2022 and first quarter of 2023. For the December, fourth quarter, the company anticipates sales to be in the range of $145,000 and $155,000.For the first quarter, the Company expects sales to be in the range of $450,000 to $600,000 with the possibility of an adjustment upwards subject to increased production capacity.お知らせ • Mar 01Alr Technologies Announces Successful Preliminary Results for the Glucurve Pet Cgm Non-Inferiority StudyALR Technologies Inc. announced preliminary results from the Non-Inferiority Study currently being conducted on the GluCurve Pet CGM. Utilizing a chemistry analyzer for the baseline, the GluCurve has thus far performed on par with the leading veterinary Blood Glucose Meter (BGM) and has met all the accuracy requirements set for human blood glucose meters in ISO: 15197:2013.お知らせ • Feb 11ALR Technologies Inc. Announces Completion of Continuous Glucose Monitor (CGM) Integration and Provides Update on Human InitiativesALR Technologies Inc. announced the completion of its integration between the GluCurve Pet CGM platform and the Infinovo P3 CGM. Infinovo’s cutting edge P3 CGM technology is the perfect fit for the GluCurve Pet CGM, utilizing industry leading features such as factory calibration, glucose readings every three minutes, and built-in memory to store up to 14 days of data collected by the CGM. ALRT will be starting the Non-inferiority Study for the GluCurve Pet CGM this month, immediately followed with a Validation Study. With the anticipated successful results of the studies, ALR Technologies will resume talks with global pharmaceutical companies in March with a view to finalize a strategic arrangement thereafter. ALRT plans to sell a 50% stake in GluCurve Pet CGM for working capital in a structured deal which will allow a potential pharmaceutical partner to take control of the sales and marketing activities by utilizing their global presence in animal health and existing relationships with veterinary clinics worldwide for rapid adoption of the GluCurve Pet CGM. The Company has received various inquiries on the state of the human initiatives in Singapore, Canada, and elsewhere. Having received positive feedback and results on the ALRT Diabetes Solution platform for human health, these initiatives have been put on hold while working towards the commercialization of the GluCurve Pet CGM. The diabetes care industry is calling for the use of CGMs to replace Blood Glucose Meters (“BGM”). The high cost of CGMs is the primary factor holding back patients and payers from replacing BGMs with CGMs. While the ALRT Diabetes Solution is currently bundled with BGMs, the Company is focused on offering the ALRT Diabetes Solution with a cost effective CGM. ALRT is preparing for CGM clinical trial and FDA submission to be completed during 2022. ALR Technologies is targeting to offer the ALRT Diabetes Solution bundled with CGM in 2023 with pricing to compete with the standalone BGM offerings.お知らせ • Nov 11ALRT Technologies Inc. Announces the Launch of the Alrt Diabetes Solution Through a Partnership with Diabetes SingaporeALR Technologies Inc. announced the commercial launch of the ALRT Diabetes Solution through a partnership with Diabetes Singapore. On November 16, 2020, Diabetes Singapore will begin offering ALRT’s leading edge telemedicine diabetes solution to its extensive network of doctors and patients throughout Singapore. Diabetes Singapore will hire diabetes care nurses to manage the patients’ blood glucose trends. The ALRT system will perform a weekly predictive review of the patients’ records and prompt the nurses to direct the patients to their doctors when there is a need to modify therapy. Guideline-driven suggestions for therapy advancement will be provided to the doctors by the ALRT system, as well.収支内訳ALR Technologies SG の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:ALRT.F 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Dec 250-222130 Sep 250-212130 Jun 250-212131 Mar 250-182131 Dec 240-163130 Sep 240-133130 Jun 240-104131 Mar 240-94131 Dec 230-73130 Jun 230-114131 Mar 230-114131 Dec 220-114030 Jun 220-83131 Mar 220-93131 Dec 210-82030 Sep 210-73030 Jun 210-72131 Mar 210-63131 Dec 200-62130 Sep 200-71230 Jun 200-61131 Mar 200-92231 Dec 190-92230 Sep 190-72230 Jun 190-62131 Mar 190-31031 Dec 180-42030 Sep 180-42130 Jun 180-42131 Mar 180-42131 Dec 170-31030 Sep 170-30030 Jun 170-100031 Mar 170-100131 Dec 160-100130 Sep 160-101130 Jun 160-31131 Mar 160-61131 Dec 150-61130 Sep 150-611質の高い収益: ALRT.Fは現在利益が出ていません。利益率の向上: ALRT.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: ALRT.Fは利益が出ておらず、過去 5 年間で損失は年間24.4%の割合で増加しています。成長の加速: ALRT.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: ALRT.Fは利益が出ていないため、過去 1 年間の収益成長をMedical Equipment業界 ( 14.8% ) と比較することは困難です。株主資本利益率高いROE: ALRT.Fの負債は資産を上回っているため、自己資本利益率を計算することは困難です。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YHealthcare 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/29 09:12終値2026/06/26 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ALR Technologies SG Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Juan NobleTaglich Brothers, Inc.
お知らせ • Jan 02ALR Technologies SG Ltd. Announces the Successful Completion of Internal Manufacturing Testing on the GluCurve Pet CGMALR Technologies SG Pte. Ltd. announced the successful completion of internal manufacturing testing on the GluCurve Pet CGM showing accuracy results comparative to the leading veterinary Blood Glucose Meter ("BGM") and scheduling of its relaunch into the Canadian market for January 2026. One can't prick the finger of a cat or dog to check blood sugar as you would with a human, and even when you can draw blood from their ear, paw, or vein, a spot check of this nature doesn't provide the data needed to properly dose insulin or see trends as a CGM would. The company believe this is why the company have received so much interest and demand for the GluCurve pet CGM from veterinarians, pet owners, and animal health companies, because there is a desperate need for a holistic product like to manage diabetic dogs. The relaunch of the GluCurve PetCGM in the United States is planned for early second quarter 2026 through an ongoing strategic relationship with a leading veterinary distributor, followed by a global launch throughout Europe, Australia, Asia, South America, and the rest of the world. The company will announce when GluCurve is for sale in Canada and any additional updates on sales, partnerships, and other material updates as they occur.
お知らせ • May 02ALR Technologies SG Ltd. announced delayed 20-F filingOn 05/01/2025, ALR Technologies SG Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC.
お知らせ • Dec 28ALR Technologies Inc. Provides Sales Guidance for the December, Fourth Quarter of 2022 and First Quarter of 2023ALR Technologies Inc. provided sales guidance for the December, fourth quarter of 2022 and first quarter of 2023. For the December, fourth quarter, the company anticipates sales to be in the range of $145,000 and $155,000.For the first quarter, the Company expects sales to be in the range of $450,000 to $600,000 with the possibility of an adjustment upwards subject to increased production capacity.
お知らせ • Mar 01Alr Technologies Announces Successful Preliminary Results for the Glucurve Pet Cgm Non-Inferiority StudyALR Technologies Inc. announced preliminary results from the Non-Inferiority Study currently being conducted on the GluCurve Pet CGM. Utilizing a chemistry analyzer for the baseline, the GluCurve has thus far performed on par with the leading veterinary Blood Glucose Meter (BGM) and has met all the accuracy requirements set for human blood glucose meters in ISO: 15197:2013.
お知らせ • Feb 11ALR Technologies Inc. Announces Completion of Continuous Glucose Monitor (CGM) Integration and Provides Update on Human InitiativesALR Technologies Inc. announced the completion of its integration between the GluCurve Pet CGM platform and the Infinovo P3 CGM. Infinovo’s cutting edge P3 CGM technology is the perfect fit for the GluCurve Pet CGM, utilizing industry leading features such as factory calibration, glucose readings every three minutes, and built-in memory to store up to 14 days of data collected by the CGM. ALRT will be starting the Non-inferiority Study for the GluCurve Pet CGM this month, immediately followed with a Validation Study. With the anticipated successful results of the studies, ALR Technologies will resume talks with global pharmaceutical companies in March with a view to finalize a strategic arrangement thereafter. ALRT plans to sell a 50% stake in GluCurve Pet CGM for working capital in a structured deal which will allow a potential pharmaceutical partner to take control of the sales and marketing activities by utilizing their global presence in animal health and existing relationships with veterinary clinics worldwide for rapid adoption of the GluCurve Pet CGM. The Company has received various inquiries on the state of the human initiatives in Singapore, Canada, and elsewhere. Having received positive feedback and results on the ALRT Diabetes Solution platform for human health, these initiatives have been put on hold while working towards the commercialization of the GluCurve Pet CGM. The diabetes care industry is calling for the use of CGMs to replace Blood Glucose Meters (“BGM”). The high cost of CGMs is the primary factor holding back patients and payers from replacing BGMs with CGMs. While the ALRT Diabetes Solution is currently bundled with BGMs, the Company is focused on offering the ALRT Diabetes Solution with a cost effective CGM. ALRT is preparing for CGM clinical trial and FDA submission to be completed during 2022. ALR Technologies is targeting to offer the ALRT Diabetes Solution bundled with CGM in 2023 with pricing to compete with the standalone BGM offerings.
お知らせ • Nov 11ALRT Technologies Inc. Announces the Launch of the Alrt Diabetes Solution Through a Partnership with Diabetes SingaporeALR Technologies Inc. announced the commercial launch of the ALRT Diabetes Solution through a partnership with Diabetes Singapore. On November 16, 2020, Diabetes Singapore will begin offering ALRT’s leading edge telemedicine diabetes solution to its extensive network of doctors and patients throughout Singapore. Diabetes Singapore will hire diabetes care nurses to manage the patients’ blood glucose trends. The ALRT system will perform a weekly predictive review of the patients’ records and prompt the nurses to direct the patients to their doctors when there is a need to modify therapy. Guideline-driven suggestions for therapy advancement will be provided to the doctors by the ALRT system, as well.